<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6406">
  <stage>Registered</stage>
  <submitdate>30/03/2017</submitdate>
  <approvaldate>30/03/2017</approvaldate>
  <nctid>NCT03102320</nctid>
  <trial_identification>
    <studytitle>Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</studytitle>
    <scientifictitle>Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies</scientifictitle>
    <utrn />
    <trialacronym>ARCS-Multi</trialacronym>
    <secondaryid>2016-004002-33</secondaryid>
    <secondaryid>15834</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neoplasms</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Cisplatin
Treatment: drugs - Gemcitabine
Treatment: drugs - Anetumab ravtansine (BAY94-9343)

Experimental: Cholangiocarcinoma - Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with cisplatin During the main study phase anetumab ravtansine will be administered at the determined MTD in combination with cisplatin

Experimental: Adenocarcinoma of the pancreas - Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with gemcitabine During the main study phase, anetumab ravtansine will be administered at the determined MTD in combination with gemcitabine

Experimental: Other solid tumors - (Non-small cell adenocarcinoma of the lung (NSCLC adenocarcinoma), Adenocarcinoma of the breast - triple negative (TNBC), Gastric adenocarcinoma including gastroesophageal junction (GEJ Cancer, Thymic carcinoma) During the main study phase, anetumab ravtansine will be administered at dose of 6.5 mg/kg in solid tumors


Treatment: drugs: Cisplatin
Cisplatin 25 mg/m2 IV administered on day 1 and day 8 of 21 day cycle, for up to maximum 6 cycles

Treatment: drugs: Gemcitabine
Gemcitabine 1000 mg/m2 IV administered on days 1 and 8 of a 21-day cycle

Treatment: drugs: Anetumab ravtansine (BAY94-9343)
Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Maximum tolerated dose (MTD) of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine in patients with mesothelin-expressing cholangiocarcinoma and pancreatic adenocarcinoma - The highest dose of anetumab ravtansine that can be given so that not more than 1 out of 6 patients experiences a DLT (during the DLT evaluation period) will be declared as the MTD for anetumab ravtansine in combination with cisplatin or with gemcitabine</outcome>
      <timepoint>At least 3 weeks after the last patient starts treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Objective response rate (ORR) of anetumab ravtansine for monotherapy and combination therapy in mesothelin expressing advanced solid tumors - A patient is a responder if the patient has a tumor response of CR or PR, as determined per RECIST 1.1 criteria (ITMIG modified RECIST 1.1 criteria for thymic carcinoma). In the Phase 1b portion of this study, the ORR is defined separately in each indication and mesothelin expression cohort, as the number of responders divided by the number of treated patients in the indication and mesothelin expression cohort</outcome>
      <timepoint>18 weeks after last patient starts treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of serious and non-serious adverse events (AEs) - Include treatment-emergent AEs, SAEs, treatment-related AEs, AEs of special interest, and deaths.</outcome>
      <timepoint>18 weeks after last patient starts treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease control rate (DCR) - The DCR is defined as the number of patients with disease control divided by the number of treated patients.</outcome>
      <timepoint>18 weeks after last patient starts treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response (DOR) - DOR is defined in responders as the time from documentation of tumor response (CR or PR) to earlier of disease progression or death</outcome>
      <timepoint>Approximately 24 months after last patient starts treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Durable response rate (DRR) - A durable responder is defined as a responder (CR or PR) with a duration of response per RECIST 1.1 criteria (ITMIG modified RECIST 1.1 criteria for thymic carcinoma) of 180 days or more. The DRR is the number of durable responders divided by the number of treated patients.</outcome>
      <timepoint>Approximately 24 months after last patient starts treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival (PFS) - PFS is defined as time from start of treatment until disease progression according to RECIST 1.1 (ITMIG modified RECIST 1.1 criteria for thymic carcinoma) or death.</outcome>
      <timepoint>Approximately 24 months after last patient starts treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Availability of tumor tissue for mesothelin expression testing

          -  Histologically-confirmed, mesothelin-expressing metastatic or advanced non-metastatic
             disease (tumour type specific inclusion criteria)

          -  At least one measurable lesion according to either Response Evaluation Criteria in
             Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG)
             modified RECIST 1.1 as applicable

          -  Adequate bone marrow, liver, renal and coagulation function

          -  Left ventricular ejection fraction (LVEF) = 50% of the lower limit of normal (LLN)
             according to local institutional ranges

          -  Eastern Cooperative Oncology Group (ECOG) 0 or 1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  More than one prior anti-tubulin/microtubule agent

          -  Corneal epitheliopathy or any eye disorder that may predispose the patients to this
             condition

          -  Symptomatic Central nervous system (CNS) metastases and/or carcinomatous meningitis

          -  Contraindication to both CT and MRI contrast agents

          -  Active hepatitis B or C infection

          -  Pregnant or breast-feeding patients

          -  Tumor type specific exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>26/05/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>348</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>11/02/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC,WA</recruitmentstate>
    <hospital>Blacktown Cancer &amp; Haematology Centre - Blacktown</hospital>
    <hospital>Mid North Coast Cancer Institute - Coffs Harbour</hospital>
    <hospital>Kinghorn Cancer Centre - Darlinghurst</hospital>
    <hospital>Northern Cancer Institute - St Leonards</hospital>
    <hospital>Flinders Medical Centre - Adelaide</hospital>
    <hospital>Epworth HealthCare - Richmond</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>St John of God Healthcare - Subiaco</hospital>
    <postcode>2148 - Blacktown</postcode>
    <postcode>2450 - Coffs Harbour</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>5042 - Adelaide</postcode>
    <postcode>3122 - Richmond</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>6008 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles - Brussel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Besancon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice Cedex 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitiers Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Cloud</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Württemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bayern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Thüringen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Veneto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Málaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Graubünden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Ticino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicestershire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>North Ireland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Surrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Midlands</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The key purpose of the main part of the study is to assess efficacy and safety of anetumab
      ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid
      tumors.

      The main purpose of the safety lead-in (dose-finding) part of the study is to determine the
      safety and tolerability of anetumab ravtansine in combination with cisplatin and in
      combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination
      with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with
      gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas.

      Patients will receive anetumab ravtansine every three weeks in monotherapy for most
      indications. In cholangiocarcinoma and adenocarinoma of the pancreas, 3-weekly anetumab
      ravtansine is administered in combination with cisplatin or gemcitabine respectively (both
      administered in a 2 week on / 1 week off schedule).

      Treatment will continue until disease progression or until another criterion for withdrawal
      is met. .Efficacy will be measured by evaluating the tumor's objective response rate.
      Radiological tumor assessments will be performed at defined time points until the patient's
      disease progresses.

      Blood samples will be collected for safety, pharmacokinetic and biomarker analysis. Archival
      or fresh biopsy tissue may also be collected for review and biomarkers.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03102320</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Bayer Clinical Trials Contact</name>
      <address />
      <phone>+49 30 300139003</phone>
      <fax />
      <email>clinical-trials-contact@bayer.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>